Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

This study has been completed.

Study NCT00167999. Last updated on March 14, 2007. Information provided by Wyeth

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields

Brief Title ^†

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Official Title ^†

Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.

Brief Summary

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Detailed Description

Study Phase

Phase IV

Study Type ^†

Observational

Study Design ^†

Natural History, Longitudinal, Case Control, Prospective Study

Primary Outcome Measure ^†

Secondary Outcome Measure ^†

Condition ^†

Gram-Positive Bacterial Infections
Escherichia Coli Infections
Klebsiella Infections

Intervention ^†

Drug: piperacillin-tazobactam

MEDLINE PMIDs

Links

Recruitment Information Fields

Recruitment Status ^†

Completed

Enrollment ^†

200

Start Date ^†

February 2005

Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

Eligible patients of either sex, 15 years of age or older
Patients who are admitted to the department of hematology and oncology
Provide written informed consent

Exclusion Criteria:

Patients who have hypersensitivity to β-lactam antibiotics
Female who are pregnant or breast-feeding
Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Gender

Both

Ages

15 Years and older

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

Korea, Republic of

Administrative Information Fields

NCT ID ^†

NCT00167999

Organization ID

0910X-101676

Secondary IDs ^††

Study Sponsor ^†

Wyeth

Collaborators ^††

Investigators ^†

Study Director:

Medical Monitor

Wyeth

Information Provided By

Wyeth

Verification Date

March 2007

First Received Date ^†

September 11, 2005

Last Updated Date

March 14, 2007

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.